Gilead’s focus shifts from hepatitis C to CAR-T
Cost of Novartis’ revolutionary therapy is obstacle, says CMO.
Gilead has sealed a deal to acquire cell therapy leader Kite for just under $12 billion.
Innovators will need to quantify value to bring costly drugs to market.
First patients could be treated in 2019.
Kite eyes possible CAR-T launch next year.
Panel unanimously back CTL019